- Home
- PFLT vs GERN Comparison
PFLT vs GERN Comparison
Compare PFLT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- GERN
- Stock Information
- Founded
- PFLT 2010
- GERN 1990
- Country
- PFLT United States
- GERN United States
- Employees
- PFLT N/A
- GERN N/A
- Industry
- PFLT Finance: Consumer Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- GERN Health Care
- Exchange
- PFLT Nasdaq
- GERN Nasdaq
- Market Cap
- PFLT 1.0B
- GERN 974.5M
- IPO Year
- PFLT N/A
- GERN 1996
- Fundamental
- Price
- PFLT $10.57
- GERN $1.46
- Analyst Decision
- PFLT Buy
- GERN Buy
- Analyst Count
- PFLT 6
- GERN 7
- Target Price
- PFLT $11.17
- GERN $4.17
- AVG Volume (30 Days)
- PFLT 768.4K
- GERN 9.1M
- Earning Date
- PFLT 08-11-2025
- GERN 08-07-2025
- Dividend Yield
- PFLT 11.64%
- GERN N/A
- EPS Growth
- PFLT N/A
- GERN N/A
- EPS
- PFLT 0.86
- GERN N/A
- Revenue
- PFLT $232,975,000.00
- GERN $116,293,000.00
- Revenue This Year
- PFLT $45.52
- GERN $160.12
- Revenue Next Year
- PFLT $8.87
- GERN $55.01
- P/E Ratio
- PFLT $12.26
- GERN N/A
- Revenue Growth
- PFLT 49.56
- GERN 22264.04
- 52 Week Low
- PFLT $8.82
- GERN $1.17
- 52 Week High
- PFLT $12.02
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- PFLT 61.46
- GERN 48.21
- Support Level
- PFLT $10.44
- GERN $1.36
- Resistance Level
- PFLT $10.59
- GERN $1.44
- Average True Range (ATR)
- PFLT 0.14
- GERN 0.09
- MACD
- PFLT 0.03
- GERN -0.01
- Stochastic Oscillator
- PFLT 90.83
- GERN 39.58
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.